SCHMALLENBERG VIRUS TREATMENT MARKET ANALYSIS

Schmallenberg Virus Treatment Market, By Treatment Type Antiviral Drugs, Anti-inflammatory Drugs, Analgesics, Vaccines, Others), By Animal Type (Cattle, Sheep, Goats, Others), By End User (Veterinary Hospitals and Clinics, Research Institutions, Veterinary Pharmacies and Drug Store and Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Recent Developments

New product launches

Zoetis launched a new vaccine for SBV in Europe in 2015. The vaccine, called Zulvac SBV, is a new Schmallenberg vaccine licensed for use in cattle and sheep in two doses at a three week interval.

Acquisition and partnerships

In September 2022, Zoetis acquired Jurox, one of the providers of livestock and companion animal products. The acquisition of Jurox brings Zoetis a range of important products primed for greater global expansion and a valuable animal health portfolio, including Alfaxan, a leading anesthetic product for companion animals.
In September 2022, Merck Animal Health, one of the leading animal healthcare company, announced that it had signed a definitive agreement to acquire Vence, an innovator in virtual fencing for rotational grazing and livestock management.